Atypical antipsychotic medications in the management of disruptive behaviors in children: Safety guidelines and recommendations

    Authors

    C. McKinney;K. Renk

    Comments

    Authors: contact us about adding a copy of your work at STARS@ucf.edu

    Abbreviated Journal Title

    Clin. Psychol. Rev.

    Keywords

    Atypical antipsychotic medication; Children; Adolescent; Disruptive; behavior; NEUROLEPTIC MALIGNANT SYNDROME; OPEN-LABEL; LONG-TERM; 2ND-GENERATION; ANTIPSYCHOTICS; SUBAVERAGE INTELLIGENCE; RISPERIDONE TREATMENT; AUTISTIC; DISORDER; CONDUCT PROBLEMS; ADOLESCENTS; DISCONTINUATION; Psychology, Clinical

    Abstract

    Use of atypical antipsychotic medications (AAMs) in the treatment of Disruptive Behavior (DB) in children and adolescents has increased dramatically worldwide. However, with exception of using risperidone (i.e., for the management of irritability associated with Autism, manic and mixed episodes associated with Bipolar I Disorder, and Schizophrenia) and aripiprazole (i.e., for manic and mixed episodes associated with Bipolar I Disorder and Schizophrenia), the Food and Drug Administration (FDA) has not approved the use of AAMs in children and adolescents. Although research on use of these medications in children and adolescents has increased, mechanisms of action and long-term outcomes remain poorly understood or unknown. Particularly concerning is that use of these medications in children and adolescents may impact cognitive, social, and physical development, as side effects may interfere with activities in their educational setting, peer networks, and recreational settings. Overall, AAMs frequently are prescribed off label, control DB through sedation rather than targeting actual causes of DB, and lead to many negative side effects with unknown long-term effects. Reconsidering the use of AAMs in managing DB is encouraged strongly. (C) 2010 Elsevier Ltd. All rights reserved.

    Journal Title

    Clinical Psychology Review

    Volume

    31

    Issue/Number

    3

    Publication Date

    1-1-2011

    Document Type

    Review

    Language

    English

    First Page

    465

    Last Page

    471

    WOS Identifier

    WOS:000288587400015

    ISSN

    0272-7358

    Share

    COinS